AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Discontinuing atomoxetine (Strattera) will not result in symptom rebound or other adverse events, even without tapering, according to research published in the February issue of the Journal of Clinical Psychopharmacology.
Some drugs that affect neurotransmitter release can bring about changes in neuroregulation when taken regularly over periods of time. When discontinued after chronic use, the patient may experience adverse effects or withdrawal symptoms in addition to a recurrence of symptoms of the illness.
Atomoxetine, approved for the treatment of attention-deficit/hyperactivity disorder (ADHD), acts as a blocker for the presynaptic norepinephrine …